Biohaven Ltd

In a Stage 2 advancing medium-term context under a longer-term downtrend, BHVN has pulled back into its rising 9/21 EMA zone and is tightly tracking above both EMAs with no exhaustion evident. RSI and Options Score remain neutral, and speculative strategy favoring clear structure supports immediate participation on this reclaim. Buy now on the pullback interaction above the EMAs.

• ↑Q4 revenue $463M, +627% YoY, driven by NERTEC ODT popularity.
• ↑Pfizer partnership provides $1.24B upfront plus milestones, boosting cash and global reach.
• ↓Valuation premium poses risk if sales growth decelerates.